menu search

MOLN / Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences

Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. In addition, members of Molecular Partners management will participate in several upcoming investor events in Switzerland during January 2023. Read More
Posted: Dec 30 2022, 01:00
Author Name: GlobeNewsWire
Views: 111779

MOLN News  

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

By GlobeNewsWire
November 2, 2023

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG ( more_horizontal

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

By GlobeNewsWire
June 27, 2023

Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023

RDT platform offers unique approach for tailored delivery of radioactive payloads to solid tumors RDT platform is focused on improving both tumor-targ more_horizontal

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

By GlobeNewsWire
June 19, 2023

Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage more_horizontal

Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting

By GlobeNewsWire
May 25, 2023

Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference

By GlobeNewsWire
May 16, 2023

Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage b more_horizontal

Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero

By Seeking Alpha
April 20, 2023

Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero

Molecular Partners: Sellers Have Disappeared, Enterprise Value Below Zero. more_horizontal

Molecular Partners to Present Additional Preclinical Data Supporting the Company's Radio DARPin Therapy Platform at AACR

By GlobeNewsWire
April 14, 2023

Molecular Partners to Present Additional Preclinical Data Supporting the Company's Radio DARPin Therapy Platform at AACR

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stag more_horizontal

Molecular Partners AG (MOLN) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 10, 2023

Molecular Partners AG (MOLN) Q4 2022 Earnings Call Transcript

Molecular Partners AG (NASDAQ:MOLN ) Q4 2022 Earnings Conference Call March 10, 2023 8:00 AM ET Company Participants Seth Lewis - Senior Vice Presiden more_horizontal


Search within

Pages Search Results: